• 原料直供
• 试剂商城
• 直接询价

分类

• {SNA} Analytical Standards, EP Standards, EP Standards A - B, Pharmacopeia Metrological Institutes Standards, 分析/色谱
• {SNA} Enzyme Inhibitors,
• {SNA} Analytical Standards, Analytical/Chromatography, Chromatography, EP Standards, EP Standards A - B, Pharmaceutical Standards, Pharmacopeia Standards
• {SNA} Analytic
• A-AM, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Enzyme Inhibitors, Enzyme Inhibitors by Type, Enzymes, Inhibitors, and Substrates, Substrate Analogs
• {SNA} Additional Standards, Analytical Standards, Chromatography, Pharmaceutical Secondary Standards, Pharmaceutical Standards,
• {SNA} Enzyme Inhibitors,

产品应用

• 黄嘌呤氧化酶(xanthine oxidase) 和吡啶合成的抑制剂。

相关文献及参考

• [2]. Reiter S, et al. Demonstration of a combined deficiency of xanthine oxidase and aldehyde oxidase in xanthinuric patients not forming oxipurinol. Clin Chim Acta. 1990 Mar 15;187(3):221-34.
• Gibbings, S., et al., Xanthine Oxidoreductase Promotes The Inflammatory State Of Mononuclear Phagocytes Through Effects On Chemokine Expression, Peroxisome Proliferator-activated Receptor-{gamma} Sumoylation, And HIF-1{alpha}. J. Thorac. Cardiovasc. Surg. 286 , 961-75, (2011)
• Merck: 14,279
• Merck: 14,279 Beilstein:26(3/4)4298
• [1]. Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114.
• [1]. Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114.
• [2]. Reiter S, et al. Demonstration of a combined deficiency of xanthine o

安全信息

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - man
DOSE/DURATION           : 120 mg/kg/4W-I
TOXIC EFFECTS :
   Blood - other changes
   Skin and Appendages - dermatitis, allergic (after systemic exposure)
   Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
   CEDEDE Clinical and Experim

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 42 mg/kg/7D-I
TOXIC EFFECTS :
   Kidney, Ureter, Bladder - other changes
   Skin and Appendages - dermatitis, other (after systemic exposure)
REFERENCE :
   AJMEAZ American Journal of Medicine.  (Technical Pub., 875 Third Ave., New
   York, NY 10022) V.1-    1946-  Volume(issue)/page/year: 76,47,1984

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSE

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Human - woman
DOSE/DURATION           : 88 mg/kg/22D-I
TOXIC EFFECTS :
   Blood - leukopenia
REFERENCE :
   ARDIAO Annals of the Rheumatic Diseases.  (British Medical Journal, Box
   560B, Kennebunkport, ME 04041)  V.1-    1939-  Volume(issue)/page/year:
   40,245,1981

TYPE OF TEST            : TDLo - Lowest published toxic dos

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 298 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   YAKUD5 Gekkan Yakuji.  Pharmaceuticals Monthly.  (Yakugyo Jihosha, Inaoka
   Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan)  V.1-   1959-
   Volume(issue)/page/year: 23,715,1981

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE                    : 100 mg/kg
SEX/DURATION            : female 10 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
   JJPAAZ Japanese Journal of Pharmacology.  (Japanese Pharmacological Soc.,
   c/o Dept. of Pharmacology, Faculty of Medicine, Kyoto Univ., Sakyo-ku, Kyoto
   606, Japan)  V.1-    1951-  Volume(issue)/page/year: 22,201,1972

TYPE OF TEST            : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE                    : 50 mg/kg
SEX/DURATION            : female 10 day(s) after conception
TOXIC EFFECTS :
   Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death,
   e.g., stunted fetus)
   Reproductive - Specific Developmental Abnormalities - craniofacial
   (including nose and tongue)
   Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
   JJPAAZ Japanese Journal of Pharmacology.  (Japanese Pharmacological Soc.,
   c/o Dept. of Pharmacology, Faculty of Medicine, Kyoto Univ., Sakyo-ku, Kyoto
   606, Japan)  V.1-    1951-  Volume(issue)/page/year: 22,201,1972

其他信息

• 用途一:抗痛风药，用于治疗痛风、痛风性肾病等
• 别嘌醇价格(试剂级):更新日期 产品编号 产品名称 包装 价格 2014/06/02 A0907 别嘌呤醇 Allopurinol 250G 3170元 2014/06/02 A0907 别嘌呤醇 Allopurinol 25G 610元 2010/06/21 121830050 别嘌醇 4-Hydroxypyrazolo[3,4-d]pyrimidine 98% 5 GR 459元
• Sigma Aldrich:315-30-0(sigmaaldrich)
• 类别:有毒物品
• 用途二:别嘌呤醇及其代谢产物别黄嘌呤，均有抑制利黄嘌呤氧化酶的作用，进而使尿酸合成受阻，降低血中尿酸浓度，减少尿酸盐在骨、关节及肾脏的沉着。临床用于痛风、痛风性肾病。孕妇慎用；部分病人可出现皮疹、胃肠道反应及肝和造血系统损害，如转氨酶升高和白细胞减少；与抗癌药6-巯基嘌呤合用时，要将6-巯基嘌呤剂量减至常量的1/4。多饮水，以利尿酸排出。
• 上游原料:水合肼 --> 氰乙酸乙酯 --> 氰乙酰胺 --> 乙氧甲叉氰乙酸乙酯 --> 3-氨基-4-乙氧羰基吡唑
• 用途三:抗痛风药。适用于原发性或继发性血清尿酸增多的各种疾病，如痛风、急性或慢性白血病等。
• Alfa Aesar:4-羟基吡唑并[3,4-d]嘧啶,98% 4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine, 98%(315-30-0)
• Allopurinol is an anti-urolithic Xanthine oxidase inhibitor that decreases uric acid production.
• MSDS 信息:1H-Pyrazolo[3,4-d]pyrimidin-4-ol(315-30-0).msds
• MOL 文件:315-30-0.mol
• 方法一:将氰乙酸乙酯、原甲酸三乙酯、乙酐放在反应罐中回流反应4h，缩合得到α-乙氧次甲基氰乙酸乙酯：再将其溶解在乙醇中，加入水合肼，加热回流反应6h，得3-氨基-4-乙氧羰基吡唑；最后与甲酰胺一起加热回流反应8h，环合得到别嘌醇。用蒸馏水溶解，活性炭脱色，得精制的别嘌醇。对氰乙酸乙酯计，总收率41.8%
• 毒性分级:高毒
• 急性毒性:口服- 大鼠 LD >; 500 毫克/ 公斤; 口服- 小鼠 LD50: 78 毫克/公斤
• 灭火剂:水, 二氧化碳, 干粉, 泡沫
• 可燃性危险特性:可燃, 火场排出含氮氧化物辛辣刺激烟雾
• TCI Shanghai:别嘌呤醇 Allopurinol,>;98.0%(T)(315-30-0)
• 图谱信息:别嘌醇(315-30-0)质谱(MS) 别嘌醇(315-30-0)红外图谱(IR2) 别嘌醇(315-30-0)红外图谱(IR1)
• 储运特性:库房低温, 通风, 干燥; 与食品原料分开存放
• 水中溶解度: 0.35 g/L (25°C) ，溶于稀碱和稀酸，实际上不溶于大多数有机溶剂。
• Acros Organics:4-羟基吡唑[3，4-D]嘧啶 4-Hydroxypyrazolo[3,4-d]pyrimidine, 98%(315-30-0)
• 用途四:黄嘌呤氧化酶(xanthine oxidase) 和吡啶合成的抑制剂。